Effect of doxycyline in chronic obstructive pulmonary disease - An exploratory study

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Biochemistry

Background:

• Chronic obstructive pulmonary disease (COPD) is characterized by progressive lung function decline due to mechanisms including oxidative stress, inflammation, and protease-antiprotease imbalance.
• Doxycycline, a tetracycline antibiotic, exhibits non-antimicrobial properties, including matrix metalloproteinases (MMP) inhibition, relevant to inflammatory conditions.

Purpose of the Study:

• To assess the therapeutic effect of doxycycline as an add-on therapy in patients with chronic obstructive pulmonary disease (COPD).

Main Methods:

• A randomized prospective study involving two groups of COPD patients (n=30 each).
• Group 1 received standard therapy; Group 2 received standard therapy plus doxycycline (100 mg daily).
• Assessments after 3 months included lung function (FEV1/FVC), COPD Assessment Test (CAT), St. George's Respiratory Questionnaire (SGRQ), oxidative stress markers, inflammatory cytokines, and MMP levels.

Main Results:

• Doxycycline add-on therapy significantly reduced oxidative stress markers (LPO, TOS) and inflammatory cytokines (IL-6, TNF-α, IL-8).
• Significant decreases in MMP-2 and MMP-9/TIMP-1 ratio were observed, correlating with reduced total oxidative stress (TOS).
• Multivariate analysis identified TNF-α as a key discriminant, with its expression inversely correlated with FEV1/FVC changes.

Conclusions:

• Doxycycline demonstrated antioxidant, anti-inflammatory, and anti-MMP activities in COPD patients.
• These properties may contribute to improved lung function and quality of life, suggesting a potential therapeutic role for doxycycline beyond its antibiotic effects in COPD.